Cargando…

Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom’s Macroglobulinemia

Secondary myelodysplasia (MDS) and acute myeloid leukemia (AML) are frequent long term complications in Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM) patients. Although disease-related immune-suppression plays a crucial role in leukemogenesis there is great concern that t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ricci, Francesca, Tedeschi, Alessandra, Montillo, Marco, Morra, Enrica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152453/
https://www.ncbi.nlm.nih.gov/pubmed/21869917
http://dx.doi.org/10.4084/MJHID.2011.031
_version_ 1782209766291931136
author Ricci, Francesca
Tedeschi, Alessandra
Montillo, Marco
Morra, Enrica
author_facet Ricci, Francesca
Tedeschi, Alessandra
Montillo, Marco
Morra, Enrica
author_sort Ricci, Francesca
collection PubMed
description Secondary myelodysplasia (MDS) and acute myeloid leukemia (AML) are frequent long term complications in Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM) patients. Although disease-related immune-suppression plays a crucial role in leukemogenesis there is great concern that therapy may further increase the risk of developing these devastating complications. Nucleoside analogs (NA) and alkylating agents are considered appropriate agents in the treatment of both CLL and WM patients. Prolonged immunosuppression related to NA therapy and the incorporation of these agents or their metabolites into DNA, with potentially mutagenic action, leads to speculation that their therapeutic use might be responsible for an increased incidence of second cancer especially when combined with other DNA damaging agents like alkylating agents. In this review the published studies considering the occurrence of secondary MDS and AML in CLL and WM patients are reported and the potential role of chemotherapeutic agents in leukemogenesis is discussed.
format Online
Article
Text
id pubmed-3152453
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Università Cattolica del Sacro Cuore
record_format MEDLINE/PubMed
spelling pubmed-31524532011-08-25 Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom’s Macroglobulinemia Ricci, Francesca Tedeschi, Alessandra Montillo, Marco Morra, Enrica Mediterr J Hematol Infect Dis Original Articles Secondary myelodysplasia (MDS) and acute myeloid leukemia (AML) are frequent long term complications in Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM) patients. Although disease-related immune-suppression plays a crucial role in leukemogenesis there is great concern that therapy may further increase the risk of developing these devastating complications. Nucleoside analogs (NA) and alkylating agents are considered appropriate agents in the treatment of both CLL and WM patients. Prolonged immunosuppression related to NA therapy and the incorporation of these agents or their metabolites into DNA, with potentially mutagenic action, leads to speculation that their therapeutic use might be responsible for an increased incidence of second cancer especially when combined with other DNA damaging agents like alkylating agents. In this review the published studies considering the occurrence of secondary MDS and AML in CLL and WM patients are reported and the potential role of chemotherapeutic agents in leukemogenesis is discussed. Università Cattolica del Sacro Cuore 2011-07-09 /pmc/articles/PMC3152453/ /pubmed/21869917 http://dx.doi.org/10.4084/MJHID.2011.031 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Ricci, Francesca
Tedeschi, Alessandra
Montillo, Marco
Morra, Enrica
Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom’s Macroglobulinemia
title Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom’s Macroglobulinemia
title_full Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom’s Macroglobulinemia
title_fullStr Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom’s Macroglobulinemia
title_full_unstemmed Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom’s Macroglobulinemia
title_short Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom’s Macroglobulinemia
title_sort therapy-related myeloid neoplasms in chronic lymphocytic leukemia and waldenstrom’s macroglobulinemia
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152453/
https://www.ncbi.nlm.nih.gov/pubmed/21869917
http://dx.doi.org/10.4084/MJHID.2011.031
work_keys_str_mv AT riccifrancesca therapyrelatedmyeloidneoplasmsinchroniclymphocyticleukemiaandwaldenstromsmacroglobulinemia
AT tedeschialessandra therapyrelatedmyeloidneoplasmsinchroniclymphocyticleukemiaandwaldenstromsmacroglobulinemia
AT montillomarco therapyrelatedmyeloidneoplasmsinchroniclymphocyticleukemiaandwaldenstromsmacroglobulinemia
AT morraenrica therapyrelatedmyeloidneoplasmsinchroniclymphocyticleukemiaandwaldenstromsmacroglobulinemia